Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
-
There has been some controversy on whether the costs of omalizumab outweigh its benefits for severe persistent allergic asthma. ⋯ Although the cost-effectiveness of omalizumab is more favorable under the PAS price, it represents good value for money only in severe subgroups and under optimistic assumptions regarding asthma mortality and improvement in health-related quality of life. For these reasons, omalizumab should be carefully targeted to ensure value for money.